Show summary Hide summary
Rosie O’Donnell has been candid about her experience with the diabetes drug Mounjaro, revealing a deliberate, measured approach to dosing as she reshaped her health. The former talk show star has shared details about how she increased strength gradually, how the medication affected her appetite, and why she prefers a slow pace. Her comments surfaced during recent media appearances and social posts.
Rosie’s step-by-step dosing strategy for Mounjaro
On the Bleep! With Ana Navarro podcast, O’Donnell outlined a staged plan that she followed over several years. She emphasized patience and small increments rather than rapid escalation.
Sophia Laforteza of Katseye announces hiatus: comes months after Manon Bannerman’s exit
Delta to return to Tokyo Narita hub in 2027: 7-year comeback
Timeline of doses
- Year 1: began at the lowest dose, 2.5 mg.
- Year 2: increased to 5 mg and maintained it for a year.
- Year 3: spent a year at 7.5 mg and plans one final increase.
She says she intends to raise the dosage only one more time and then hold steady.
Why she chose a gradual rise in dose
O’Donnell explained her reasoning plainly.
- She wanted to avoid rapid change that felt overwhelming.
- She was mindful of past experiences with fast weight loss.
- She listened to her body and to doctors’ advice.
She described preferring a slow pace so she wouldn’t feel sick and to reduce difficult reactions from others to sudden weight loss.
Side effects and real-world reaction
When asked about common gastrointestinal complaints tied to GLP-1 drugs, O’Donnell was emphatic.
She says she has never experienced the typical urgent bathroom visits that some users report. She credited her low starting dose and slow increases for minimizing problems.
Her doctor regularly encouraged higher doses, but she resisted advancing until she felt ready.
Changes to appetite and daily habits
O’Donnell first disclosed her use of Mounjaro in early 2023 on TikTok, after starting treatment two months earlier. She reported marked shifts in cravings and routine.
- Appetite dropped significantly, and thoughts about food lessened.
- She replaced multiple Diet Cokes with mostly water.
- She reduced sugar intake and noticed early weight loss.
At that stage she had lost about 10 pounds and later shared ongoing progress on social media.
Public statements and advocacy around access
In interviews this year, O’Donnell framed the medication as transformative for her health. She has used frank language about the stigma around obesity and the barriers many face in getting treatment.
She told reporters the drug has “saved” her life and said she would rather see prices fall than do paid endorsements. Her remarks stressed empathy for people living with weight stigma.
O’Donnell also described feeling stronger and more in control in her changed body, tying physical shifts to improvements in energy and confidence.
Context on Mounjaro and GLP-1 medications
Mounjaro is part of a class of drugs that affect appetite and blood sugar control. Celebrities and the public alike have reported weight changes and lifestyle shifts while using GLP-1 therapies.
Medical professionals urge patients to work with their doctors to find the right dose and monitor side effects. O’Donnell’s experience underscores a cautious, personalized approach.
